This is a paid press release. Contact the press release distributor directly with any inquiries.
Zealand Pharma Announces Financial Results for the First Half of 2026
Company announcement – No. 39 / 2026
A landmark first half defined by key milestones delivered for leading obesity assets, and a continued momentum building across all fronts of our Metabolic Frontier 2030 strategy.
-
Announced decision to advance petrelintide into Phase 3 trials in H2 2026 following positive Phase 2 results, demonstrating double-digit weight loss with a tolerability profile largely comparable to placebo, supporting its potential to redefine the weight management experience for people living with obesity or overweight.
-
Boehringer Ingelheim presented positive results from the SYNCHRONIZETM-1 and SYNCHRONIZETM-MASLD Phase 3 trials with survodutide, supporting its potential as a differentiated treatment option for people living with obesity or overweight and metabolic dysfunction, with readouts of the remaining key Phase 3 obesity trials expected later in the year.
-
Initiated a Phase 1b clinical trial with ZP9830, a novel Kv1.3 ion channel blocker, in people with psoriasis, marking the first step towards establishing proof-of-concept for ZP9830 with broad potential across autoimmune and inflammatory diseases.
-
Continued active balance sheet management through launch of a USD 200 million share buyback program and USD 100 million royalty monetization of a non-core asset
Copenhagen, Denmark, August 13, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced the interim report for the six months ended June 30, 2026, and provided a corporate update.
A first half of defining moments
“In 2026 to date, we have executed with pace and precision across our pipeline,” Adam Steensberg, President and Chief Executive Officer at Zealand Pharma said. “We delivered on the key commitments we set out at the start of the year, while maintaining our sharp focus on the next wave of metabolic health innovation. What stands out this half is not just the depth and breadth of progress, but what it signals about where the field is heading. At ADA 2026, the consensus among key opinion leaders on unmet needs in chronic weight management was clear: tolerability, treatment persistence, and patient experience now define the conversation, and we believe amylin is emerging as the answer. The opportunity in front of us has never been clearer.”
Key financial results for H1 2026
|
Operating expenses, excl. OOI1 |
||
